Nitric oxide (NO) became a sudden celebrity in the early 1990s, as scientists recognized that the gas long known as a component of cigarette smoke and smog is also a vital chemical messenger within the body, but no one has yet been able to channel the academic understanding of NO into successful new medicines. Novan Inc. believes it can succeed where others have failed – the start-up aims first to create a topical treatment for acne, and then to pursue other first-in-class treatments in the field of dermatology.
Novan Inc.
4222 Emperor Boulevard
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.
The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.
